Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for PBH and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for PBH and 80,000+ other tickers.
See exactly how PBH's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PBH and 80,000+ other tickers.
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore…
On October 23, 2026, Prestige Consumer Healthcare Inc (PBH) shares fell 3.4%, closing at $47.80. The stock has experienced significant volatility, with a 52-wee
PBH's brand-building, acquisitions and e-commerce growth support fiscal 2027 revenue gains, but competition and currency risks remain key challenges.
TARRYTOWN, N.Y., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2027 second quarter and first half earnings release on Thursday, November 5, 2026 before the opening of the market.
Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.
BP and PBH made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 1, 2026.